Related references
Note: Only part of the references are listed.Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
Constantine S. Tam et al.
BLOOD (2022)
Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment
Zhenghao Chen et al.
BLOOD (2022)
Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
Arnon P Kater et al.
LANCET ONCOLOGY (2022)
Macrophage- and BCR- but not TLR-derived signals support the growth of CLL and Richter Syndrome murine models in vivo
Claudio Martines et al.
BLOOD (2022)
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
Carsten U. Niemann et al.
BLOOD (2021)
TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target
Emma Kennedy et al.
BLOOD (2021)
Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
Marco Haselager et al.
CELL DEATH AND DIFFERENTIATION (2021)
miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors
Sonali Sharma et al.
BLOOD (2021)
Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
Raquel Delgado et al.
CANCERS (2021)
Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
Arnon P. Kater et al.
BLOOD ADVANCES (2021)
Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
William G. Wierda et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Mitochondrial DNA in inflammation and immunity
Joel S. Riley et al.
EMBO REPORTS (2020)
Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL
Marco Haselager et al.
BLOOD (2020)
Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations
Mark-David Levin et al.
BMJ OPEN (2020)
Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
Marco V. Haselager et al.
FRONTIERS IN ONCOLOGY (2020)
BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo
Cedric Schleiss et al.
SCIENTIFIC REPORTS (2019)
Ibrutinib and Venetoclax for First-Line Treatment of CLL
Nitin Jain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib
Eman L. Dadashian et al.
CANCER RESEARCH (2019)
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Michael Hallek et al.
BLOOD (2018)
Role of Bruton's tyrosine kinase in B cells and malignancies
Simar Pal Singh et al.
MOLECULAR CANCER (2018)
A multiprotein supercomplex controlling oncogenic signalling in lymphoma
James D. Phelan et al.
NATURE (2018)
Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy
Jan A. Burger et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Mitochondrial inner membrane permeabilisation enables mtDNA release during apoptosis
Joel S. Riley et al.
EMBO JOURNAL (2018)
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia
J. Deng et al.
LEUKEMIA (2017)
Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition
E. Slinger et al.
LEUKEMIA (2017)
Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia
M. H. A. van Attekum et al.
ONCOGENE (2017)
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy
Dan A. Landau et al.
NATURE COMMUNICATIONS (2017)
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib
Jan A. Burger et al.
JCI INSIGHT (2017)
Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation
Alison Yeomans et al.
BLOOD (2016)
A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study
A. C. Rawstron et al.
LEUKEMIA (2016)
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
Mary Ann Anderson et al.
BLOOD (2016)
TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells
Patricia K. A. Mongini et al.
JOURNAL OF IMMUNOLOGY (2015)
Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK
Sergey Krysov et al.
BLOOD (2014)
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL
Sarah E. M. Herman et al.
BLOOD (2014)
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity
S. Cheng et al.
LEUKEMIA (2014)
IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells
Maria Fernanda Pascutti et al.
BLOOD (2013)
Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia
Ghasem Ghalamfarsa et al.
CYTOKINE (2013)
Biology of Chronic Lymphocytic Leukemia in Different Microenvironments Clinical and Therapeutic Implications
Yair Herishanu et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
Chronic Lymphocytic Leukemia Cells Are Activated and Proliferate in Response to Specific T Helper Cells
Audun Os et al.
CELL REPORTS (2013)
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2011)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
Intraclonal Complexity in Chronic Lymphocytic Leukemia: Fractions Enriched in Recently Born/Divided and Older/Quiescent Cells
Carlo Calissano et al.
MOLECULAR MEDICINE (2011)
Dichotomy in NF-κB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering
J. M. Tromp et al.
ONCOGENE (2010)
CD40/CD40L signaling and its implication in health and disease
Antonios Chatzigeorgiou et al.
BIOFACTORS (2009)
Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia
Meike Vogler et al.
BLOOD (2009)
c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches
Delfine Y. H. Hallaert et al.
BLOOD (2008)
Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity
Laura A. Smit et al.
BLOOD (2007)
The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease
P. G. Longo et al.
LEUKEMIA (2007)
Share Paper
